These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27529943)

  • 21. [THERAPEUTIC AND DIETARY CORRECTION OF PROTEIN-ENERGY DEFICIENCY WITH A DRY PROTEIN COMPOSITE FORMULA IN PATIENTS WITH PULMONARY TUBERCULOSIS IN A TUBERCULOSIS HOSPITAL].
    Tuberk Biolezni Legkih; 2010; (2):40-3. PubMed ID: 27529942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Adverse reactions during intravenous drop chemotherapy of disseminated fibrous-cavernous pulmonary tuberculosis].
    Milinder NM
    Sov Med; 1979 Nov; (11):64-7. PubMed ID: 524200
    [No Abstract]   [Full Text] [Related]  

  • 23. Treatment interruptions among patients with tuberculosis in Russian TB hospitals.
    Belilovsky EM; Borisov SE; Cook EF; Shaykevich S; Jakubowiak WM; Kourbatova EV
    Int J Infect Dis; 2010 Aug; 14(8):e698-703. PubMed ID: 20627786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incidence and pattern of recurrent side effects in persons with different haptoglobin phenotypes during chemotherapy of pulmonary tuberculosis].
    Ubaĭdullaev AM; Tashpulatova FK; Kazakov KS
    Probl Tuberk; 1998; (4):23-4. PubMed ID: 9771032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Side effects of chemotherapy in patients with pulmonary tuberculosis and concomitant diseases].
    Nikolaeva OD
    Lik Sprava; 2003; (3-4):74-8. PubMed ID: 12889365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Changes in the patients' mental status in the tolerability of antituberculous drugs].
    Mordyk AV; Briukhanova NS; Kazakov AV
    Probl Tuberk Bolezn Legk; 2009; (3):38-42. PubMed ID: 19455986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influence of adverse reactions due to chemotherapy on life quality indices in patients with infiltrative pulmonary tuberculosis].
    Mordyk AV; Antropova VV
    Probl Tuberk Bolezn Legk; 2008; (9):44-6. PubMed ID: 19065734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
    Wada M; Yoshiyama T; Ogata H; Ito K; Mizutani S; Sugita H
    Kekkaku; 1999 Apr; 74(4):353-60. PubMed ID: 10355221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background].
    Tashpulatova FK
    Probl Tuberk Bolezn Legk; 2003; (6):17-20. PubMed ID: 12918234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adverse reactions of antituberculous agents].
    Kobashi Y; Niki Y; Kawane H; Matsushima T
    Kekkaku; 1998 Jul; 73(7):485-90. PubMed ID: 9739581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Managing the adverse events of antitubercular agents].
    Perriot J; Chambonnet E; Eschalier A
    Rev Mal Respir; 2011 Apr; 28(4):542-55. PubMed ID: 21549908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of pulmonary tuberculosis in the elderly.
    Das SK; Mukherjee RS; Ghosh IN; Halder AK; Saha SK
    J Indian Med Assoc; 2007 Aug; 105(8):432, 436, 438-9. PubMed ID: 18236905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
    Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
    Kekkaku; 2000 Dec; 75(12):699-704. PubMed ID: 11201137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effectiveness and safety of sparfloxacine in combined therapy for tuberculosis].
    Sokolova GB; Khaĭmenova TIa; Borisov SE; Lazareva IaV; Bogadel'nikova IV; Biron MG; Mozhokina GN; Tsibanev AA
    Probl Tuberk Bolezn Legk; 2007; (6):40-5. PubMed ID: 17674470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
    Bhushan B; Chander R; Kajal NC; Ranga V; Gupta A; Bharti H
    Indian J Tuberc; 2014 Oct; 61(4):318-24. PubMed ID: 25675695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Side effects of antituberculous drugs observed within six months after admission. Tuberculosis Research Committee, Ryoken (author's transl)].
    Kekkaku; 1975 Jun; 50(6):161-7. PubMed ID: 1185917
    [No Abstract]   [Full Text] [Related]  

  • 38. [Study on the efficacy and safety of short-term treatment including fluoroquinolones anti-tuberculosis drugs for rifampicin resistant pulmonary tuberculosis].
    Kang WL; Xie YG; Tan WG; Chu NH; Li L; You YH; Yang YZ; Wang XM; Yan XL; Miao ZP; Duanmu HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Feb; 30(2):179-83. PubMed ID: 19565883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Follow-up of antitubercular treatment].
    Gavira R; Gómez F; Otero MJ; Barrueco M; Domínguez-Gil A
    Rev Clin Esp; 1994 Sep; 194(9):677-81. PubMed ID: 7984795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.